TY - JOUR
T1 - Cefmenoxime. Clinical, bacteriologic, and pharmacologic studies
AU - LeFrock, Jack L.
AU - Molavi, Abdolghader
AU - McCloskey, Richard V.
AU - Rolston, Kenneth
AU - Chandrasekar, Pranatharthi
AU - Henao, Libia
AU - Smith, Bruce R.
AU - Kannangara, Walter
AU - Schell, Ronald F.
AU - Carr, Bernice B.
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1984/7
Y1 - 1984/7
N2 - Cefmenoxime, a new semisynthetic third-generation cephalosporin, was evaluated in 105 patients (45 men and 60 women) with the following infections: skin or skin structure (33), pulmonary (22), urinary tract (30), and septicemia (20). Forty-two infections were hospital-acquired, 85 patients had underlying diseases, 29 patients required concomitant surgery, and 32 patients had positive results of blood culture. Cefmenoxime dosages ranged from 4 to 12 g per day intravenously for one and a half to 51 days. Cultures revealed 183 organisms in the 105 patients. Minimal inhibitory concentrations were obtained for cefmenoxime, cefoperazone, cefotaxime, cefamandole, cefoxitin, and moxalactam. Cefmenoxime and cefotaxime exhibited nearly equivalent activities against all organisms tested and were the most active agents tested against all aerobic and facultative organisms except Staphylococcus aureus. Mean serum peak and trough levels obtained after 2 g every six hours were 84.1 μg/ml (peak), 8.3 μg/ml (trough); and after 2 g every four hours, 106 μg/ml (peak) and 10.9 μg/ml (trough). Of 105 infections, 86 were clinically cured, three were not cured, and 16 were not evaluable. Safety studies revealed 24 transient reactions in 23 patients including eosinophilia, diarrhea, leukopenia, rash, elevated liver enzyme levels, Antabuse effect, and phlebitis. On the basis of these clinical and in vitro results, cefmenoxime is a safe drug for the treatment of infections caused by gram-negative and gram-positive aerobic organisms.
AB - Cefmenoxime, a new semisynthetic third-generation cephalosporin, was evaluated in 105 patients (45 men and 60 women) with the following infections: skin or skin structure (33), pulmonary (22), urinary tract (30), and septicemia (20). Forty-two infections were hospital-acquired, 85 patients had underlying diseases, 29 patients required concomitant surgery, and 32 patients had positive results of blood culture. Cefmenoxime dosages ranged from 4 to 12 g per day intravenously for one and a half to 51 days. Cultures revealed 183 organisms in the 105 patients. Minimal inhibitory concentrations were obtained for cefmenoxime, cefoperazone, cefotaxime, cefamandole, cefoxitin, and moxalactam. Cefmenoxime and cefotaxime exhibited nearly equivalent activities against all organisms tested and were the most active agents tested against all aerobic and facultative organisms except Staphylococcus aureus. Mean serum peak and trough levels obtained after 2 g every six hours were 84.1 μg/ml (peak), 8.3 μg/ml (trough); and after 2 g every four hours, 106 μg/ml (peak) and 10.9 μg/ml (trough). Of 105 infections, 86 were clinically cured, three were not cured, and 16 were not evaluable. Safety studies revealed 24 transient reactions in 23 patients including eosinophilia, diarrhea, leukopenia, rash, elevated liver enzyme levels, Antabuse effect, and phlebitis. On the basis of these clinical and in vitro results, cefmenoxime is a safe drug for the treatment of infections caused by gram-negative and gram-positive aerobic organisms.
UR - http://www.scopus.com/inward/record.url?scp=0021240773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021240773&partnerID=8YFLogxK
U2 - 10.1016/0002-9343(84)90438-8
DO - 10.1016/0002-9343(84)90438-8
M3 - Article
C2 - 6331163
AN - SCOPUS:0021240773
SN - 0002-9343
VL - 77
SP - 72
EP - 78
JO - The American journal of medicine
JF - The American journal of medicine
IS - 1
ER -